Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma

Thyroid

Volumn 21, Issue 2, 2011, Pages 197-202

  Van Doorn, Leni ^a   Eskens, Ferry A L M ^a   Visser, Theo J ^a   Van Der Lugt, Aad ^a   Mathijssen, Ron H J ^a   Peeters, Robin P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; COUMARIN DERIVATIVE; LEVOTHYROXINE; SORAFENIB; THYROTROPIN; THYROXINE;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ECHOGRAPHY; EVENING DOSAGE; FEMALE; FREE THYROXINE INDEX; HEART ATRIUM FIBRILLATION; HORMONAL THERAPY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER CELL CARCINOMA; MORNING DOSAGE; PRIORITY JOURNAL; SKIN TOXICITY; THYROID WEIGHT; THYROIDITIS; THYROTROPIN BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS; ATROPHY; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; THYROID GLAND; THYROIDITIS;

EID: 79953251489     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0234     Document Type: Article

References (32)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J 2008 Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM 2007 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134.
4. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499.
5. Le Tourneau C, Faivre S, Raymond E 2008 New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 34:37-48. (Pubitemid 351168610)
6. Costello M, O'Dwyer PJ, Ratain MJ 2006 Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95:581-586. (Pubitemid 44325897)
7. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M 2008 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
8. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219-228.
9. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664. (Pubitemid 46768841)
10. Grossman M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672.
11. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)- induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149. (Pubitemid 350207759)
12. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P 2008 The clinical implications of sunitinib- induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454.
13. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces trancient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534. (Pubitemid 47435331)
14. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355. (Pubitemid 46776140)
15. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83.
16. Makita N, Miyakawa M, Fujita T, Iiri T 2010 Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20:243-244.
17. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schöffski P 2010 Shrinkage of thyroid volume in sunitinib-treated patients with renal- cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317-322.
18. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI 2008 Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268. (Pubitemid 351201706)
19. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M 2009 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 28:515-519.
20. Solbiati L, Osti V, Cova L, Tonolini M 2001 Ultrasound of thyroid, parathyroid glands and neck lymph nodes. Eur Radiol 11:2411-2424. (Pubitemid 33114892)
21. Shu J, Zhao J, Guo D, Luo Y, Zhong W, XieW2009 Accuracy and reliability of thyroid volumetry using spiral CT and thyroid volume in a healthy, non-iodine- deficient Chinese adult population. Eur J Radiol (Epub ahead of print). doi:10.1016/j.ejrad.2009.07.030
22. Pearch EN, Farwell AP, Braverman LE 2003 Thyroiditis. N Engl J Med 348:2646-2655. (Pubitemid 36741593)
23. De Bruin TWA 1994 Iodine induced hyperthyroidism with computed tomography contrast fluids. Lancet 343: 1160-1161. (Pubitemid 24142049)
24. Braverman LE 1994 Iodine and the thyroid: 33 years of study. Thyroid 4:351-356. (Pubitemid 24295435)
25. Prummel MF, Laurberg P 2003 Interferon-alpha and autoimmune thyroid disease. Thyroid 13:547-551.
26. Vassilopoulou-Sellin R, Sella A, Dexeus FH, Theriault RL, Pololoff DA 1992 Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res 24:434-438.
27. Andres E, Limbach FX, Goichot B, Sibilia J 2002 Silent thyroiditis associated with etanercept in rheumatoid arthritis. Ann Rheum Dis 61:565. (Pubitemid 34539110)
28. Stein EM, Rivera C 2007 Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma. Thyroid 17:681-683. (Pubitemid 47311559)
29. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN 2007 Sorafenib inhibits the SORAFENIB INDUCED THYROIDITIS 201 angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792. (Pubitemid 46954055)
30. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
31. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P 2009 Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331-336.
32. Levine RJ, Vatten LJ, Horowitz GL, Qian C, Romundstad PR, Yu KF, Hollenberg AN, Hellevik AL, Asvold BO, Karumanchi SA 2009 Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 339:b4336.